Patent Grant
8383033
The present technology relates to medical implants containing a porous metal component and methods of their manufacture. In the growing field of medical devices, there is continued need to provide lightweight orthopedic implants having enhanced strength, such as implants with porous metal that can provide a three-dimensional space for bone in-growth.
Joining porous metal to a metal substrate for use with an implant can be challenging, however, because the contact points available at the interface of the materials may be limited due to the surface morphology of the porous metal construct. While various methods are known for joining powder metal materials to a metal substrate, such as sintering, welding, and brazing, there are many drawbacks. The high temperatures of sintering may affect substrate properties. Welding and brazing typically use filler materials that can adversely affect biocompatibility of the final device for medical applications. Thus, it would be desirable to provide a method for joining powder metal to an implant that operates at a lower temperature and does not require additional filler materials. Specifically, it is desirable to use diffusion bonding techniques to join a porous metal structure to a metal substrate for use in an implant.
The present technology provides methods for preparing an implant having a porous metal component. In various embodiments, the method includes preparing a loose powder mixture including a biocompatible metal powder and a spacing agent. The powder mixture is compressed onto a metal base. After being compressed, the spacing agent is removed, thereby forming a compact, which comprises a porous metal structure pressed on the metal base. The method includes sintering the compact, forming a subassembly having a porous metal component and a metal base, and aligning the subassembly with a metal substrate component of the desired final implant. A metallurgical bond is formed between the subassembly and the metal substrate component. In various embodiments, the metal base of the subassembly is diffusion bonded to the metal substrate to form an implant having a porous metal component.
In other embodiments, the method for preparing an implant having a porous metal component includes preparing a loose powder mixture comprising a biocompatible metal powder and a spacing agent, and compressing the powder mixture onto a metal base defining a metal surface. The metal base can be from a solid stock of metal material or can be a layer of powder metal material. The powder mixture is heated to remove the spacing agent and to define a plurality of pores therein, forming a compact. The compact is then sintered, forming a subassembly including a porous metal structure having a metal backing. The metal backing of the subassembly is then aligned with a metal substrate component of the desired final implant. The method includes diffusion bonding the metal backing to the metal substrate to form an implant having a porous metal component.
Still in other embodiments, the method for preparing an implant having a porous metal component includes filling or otherwise placing a base layer comprising a biocompatible metal powder into a mold. A loose powder mixture of a biocompatible metal powder and a spacing agent is prepared. The method includes spreading the loose powder mixture into the mold on top of the base layer, forming a secondary layer. A compressive force is applied to the mold, thereby concurrently compressing the loose powder mixture of the secondary layer, compressing metal of the base layer, and pressing the secondary layer onto the base layer. The spacing agent is removed, defining a plurality of pores within the secondary layer. The method further includes sintering the mold contents and forming a subassembly including a porous metal structure having a powder metal backing. The powder metal backing of the subassembly is then diffusion bonded to a metal substrate portion of an implant, forming an implant having a porous metal component.
In the Figures, certain reference numerals indicate corresponding parts throughout the several views of the drawings.
It should be noted that the figures set forth herein are intended to exemplify the general characteristics of materials, methods and devices among those of the present technology, for the purpose of the description of certain embodiments. These figures may not precisely reflect the characteristics of any given embodiment, and are not necessarily intended to define or limit specific embodiments within the scope of this technology.
The following description of technology is merely exemplary in nature of the subject matter, manufacture and use of one or more inventions, and is not intended to limit the scope, application, or uses of any specific invention claimed in this application or in such other applications as may be filed claiming priority to this application, or patents issuing therefrom.
The headings (such as “Introduction” and “Summary”) and sub-headings used herein are intended only for general organization of topics within the present disclosure, and are not intended to limit the disclosure of the technology or any aspect thereof. In particular, subject matter disclosed in the “Introduction” may include novel technology and may not constitute a recitation of prior art. Subject matter disclosed in the “Summary” is not an exhaustive or complete disclosure of the entire scope of the technology or any embodiments thereof. Classification or discussion of a material within a section of this specification as having a particular utility is made for convenience, and no inference should be drawn that the material must necessarily or solely function in accordance with its classification herein when it is used in any given composition.
The description and specific examples, while indicating embodiments of the technology, are intended for purposes of illustration only and are not intended to limit the scope of the technology. Moreover, recitation of multiple embodiments having stated features is not intended to exclude other embodiments having additional features, or other embodiments incorporating different combinations of the stated features. Specific examples are provided for illustrative purposes of how to make and use the compositions and methods of this technology and, unless explicitly stated otherwise, are not intended to be a representation that given embodiments of this technology have, or have not, been made or tested.
As used herein, the words “desirable”, “preferred” and “preferably” refer to embodiments of the technology that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred or desirable, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the technology.
As referred to herein, all compositional percentages are by weight of the total composition, unless otherwise specified. As used herein, the word “include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this technology. Similarly, the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
Although the open-ended term “comprising,” as a synonym of non-restrictive terms such as including, containing, or having, is used herein to describe and claim embodiments of the present technology, embodiments may alternatively be described using more limiting terms such as “consisting of” or “consisting essentially of.” Thus, for any given embodiment reciting materials, components or process steps, Applicants specifically envision embodiments consisting of, or consisting essentially of, such materials, components or processes excluding additional materials, components or processes (for consisting of) and excluding additional materials, components or processes affecting the significant properties of the embodiment (for consisting essentially of), even though such additional materials, components or processes are not explicitly recited in this application. For example, recitation of a composition or process reciting elements A, B and C specifically envisions embodiments consisting of, and consisting essentially of, A, B and C, excluding an element D that may be recited in the art, even though element D is not explicitly described as being excluded herein.
As referred to herein, all compositional percentages are by weight of the total composition, unless otherwise specified. Disclosures of ranges are, unless specified otherwise, inclusive of endpoints. Thus, for example, a range of “from A to B” or “from about A to about B” is inclusive of A and of B. Disclosure of values and ranges of values for specific parameters (such as temperatures, molecular weights, weight percentages, etc.) are not exclusive of other values and ranges of values useful herein. It is envisioned that two or more specific exemplified values for a given parameter may define endpoints for a range of values that may be claimed for the parameter. For example, if Parameter X is exemplified herein to have value A and also exemplified to have value Z, it is envisioned that parameter X may have a range of values from about A to about Z. Similarly, it is envisioned that disclosure of two or more ranges of values for a parameter (whether such ranges are nested, overlapping or distinct) subsume all possible combination of ranges for the value that might be claimed using endpoints of the disclosed ranges. For example, if parameter X is exemplified herein to have values in the range of 1-10, or 2-9, or 3-8, it is also envisioned that Parameter X may have other ranges of values including 1-9, 1-8, 1-3, 1-2, 2-10, 2-8, 2-3, 3-10, and 3-9.
When an element or layer is referred to as being “on”, “engaged to”, “connected to” or “coupled to” another element or layer, it may be directly on, engaged, connected or coupled to the other element or layer, or intervening elements or layers may be present. In contrast, when an element is referred to as being “directly on”, “directly engaged to”, “directly connected to” or “directly coupled to” another element or layer, there may be no intervening elements or layers present. Other words used to describe the relationship between elements should be interpreted in a like fashion (e.g., “between” versus “directly between,” “adjacent” versus “directly adjacent,” etc.). As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
Spatially relative terms, such as “inner,” “outer,” “beneath”, “below”, “lower”, “above”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. Spatially relative terms may be intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below” or “beneath” other elements or features would then be oriented “above” the other elements or features. Thus, the example term “below” can encompass both an orientation of above and below. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly.
The present technology provides methods for preparing a medical implant, including joining a porous metal component to a metal substrate of an implant. As used herein, the term “implant” may be used to refer to an entire implant, or a portion thereof. For example, an implant made in accordance with the present technology, having a porous metal component joined thereto, may constitute the entire implant, or it may be used with one or more other pieces or components that together form a final implant or implant assembly. One or more portions of the implant may be provided with a metal substrate external surface or the entire implant may define a continuous surface having a metal substrate. Generally, “joined” and “joining” are comprehensive terms used to describe all processes that affix one part to another. Many useful joining/welding processes provide the application of heat with controlled melting of base materials and a filler metal. Other useful joining processes rely on surface diffusion or solid state mechanical interlocking. Many options are available for specifically joining powder metal materials to a metal substrate portion of an implant, including sintering, various welding techniques, and brazing. However, the high temperatures of sintering may affect substrate properties, while the filler materials used in welding and brazing techniques can adversely affect biocompatibility of the final device for medical applications. For example, cobalt may melt at typical sintering temperatures.
With diffusion bonding (sometimes called sinter bonding), no additional materials are required to form a bond because the bonding relies on atomic diffusion between substrates. Accordingly, diffusion bonding techniques are attractive for biocompatible applications, providing a very clean solid state bond resulting from mechanical interlocking and alloy diffusion occurring at the joining interface of the mating components. Because diffusion bonding is conducted at lower temperatures, relative to sintering or welding, the formation of intermetallic eutectics at the joining interface is minimized or avoided altogether. In order to maintain strong and uniform bond strength, however, effective diffusion bonding may be limited by geometries. For example, the strength of a bond can be related to the number of contact points between the two mating components. Accordingly, joining a porous metal component directly to a metal substrate or a metal component of an implant by diffusion bonding can pose a problem because the number of contact points available at the joining interface between the two substrates may be limited to the particular surface morphology of the porous metal construct. Having such a limited contact area for bonding may make it difficult to achieve bonds strengths suitable for orthopedic applications.
The present technology provides methods for preparing a porous metal construct with a thin, integral, solid metal backing or metal base. As used herein, the terms “solid metal backing,” “solid metal base,” and “metal base” generally refer to a substantially non-porous metal backing, or base, that may include, as non-limiting examples, a solid metal or a compressed powder metal. This non-porous backing, or base, assists in creating a smooth surface-joining interface with an increased surface/contact area that yields a very strong, mechanically stable bond between the porous metal component and metal substrate portion of an implant when using diffusion bonding techniques.
With reference to
In step 102, the loose metal mixture is compressed together and pressed onto a metal base. Such a metal base can be a solid metal, as will be discussed below. The chemical composition of the metal base can be identical to that of the metal powder, or the composition of the metal base can be different from that of the metal powder. In various embodiments, the compression of the powder mixture includes applying an isostatic pressing technique at ambient temperature, or using cold isostatic pressing (CIP). The CIP can use a water or air mixture pressurized up to the desired pressure range of from about 5,000 to about 100,000 psi. In various embodiments, the pressure range is from about 50,000 to about 75,000 psi, or about 60,000 psi.
The spacing agent, or porogen particles, of the loose powder mixture provides the pores of the porous metal implant. The spacing agent can be removable from the mixture and it may be desirable if the spacing agent does not leave residue in the porous metal implant. It may be further desirable that the spacing agent expands or contracts to supplement the formation of pores of a desired size within the porous metal implant. The pores may range in size of from between about 1 to about 1,000 micrometers, or as otherwise desired. For example, in certain embodiments, it may be desirable to have a pore size from about 100 to about 600 micrometers. In other embodiments, it may be desirable to have a pore size from between about 500 to about 700 micrometers. The spacing agent can be selected from the group consisting of hydrogen peroxide, urea, ammonium bicarbonate, ammonium carbonate, ammonium carbamate, calcium hydrogen phosphate, naphthalene, and mixtures thereof, or can be any other suitable subliming and space forming material. Generally, the spacing agent has a melting point, boiling point, sublimation temperature, etc. of less than about 400° C., or less than about 350° C., depending on the specific materials used.
A non-polar liquid binder can be used to improve the cohesiveness of the mixture because the non-polar liquid binder keeps all mixture components in close proximity and does not dissolve the spacing agent. The non-polar liquid binder can be a volatile compound with a boiling point sufficiently close to the sublimation or decomposition point of the spacing agent. In various embodiments, that temperature difference is less than about 200° C. In still other embodiments, that difference is less than about 100° C. The close range of the sublimation temperature of the spacing agent and the boiling point of the non-polar liquid binder allows for a single step removal of the spacing agent and the non-polar liquid binder during thermal processing.
The mixture of non-polar liquid binder, spacing agent, and metal powder can be made homogenous by mixing as is known in the art. In various embodiments, the ratio of metal powder to spacing agent can be from about 1:1 up to about 10:1, or greater. The non-polar liquid binder can be in a ratio of from about 1 part binder (in milliliters) to about 10 parts of solid (spacing agent and biocompatible metal powder, in grams) up to about 1 part binder 16 to about 30 parts of solid. Altering the ratios of the mixture components and/or the particle sizes of the components can provide an implant having a higher or lower porosity, enhanced load-bearing abilities, or can help to tailor the porous metal implant for a particular region of the body. Utilizing a ratio of metal powder to spacing agent of 8:1 will provide a dense implant having very fine pores. In another example, in a mixture having a 3:1 metal powder to spacing agent ratio, if the spacing agent has a diameter of at least about 25 micrometers and the metal powder has a diameter of about 10 micrometers, large pores result. If the metal powder and spacing agent diameter sizes were reversed, smaller pores would result.
As previously mentioned, the mixture can also include metal powders of different particulate sizes. By including metal powder particulates of at least two different sizes, a porosity gradient can be achieved. The porosity gradient can be such that the porosity of the implant increases or decreases by up to about 80% across the body of the implant. The porosity gradient can be continuous and scale up (or down) to a desired amount, or the porosity gradient can include differing porosity regions (e.g., 80% porosity region transitions to a 40% porosity region which transitions to a 75% porosity region). The transitions between the regions can be continuous in the porous metal implant. To provide the different porosities, a mixture corresponding to a particular porosity is stacked on top of or adjacent to a mixture having a different porosity.
With further reference to
The thermal processing step 104 includes removing the spacing agent and the non-polar liquid binder and forming a compact. In an exemplary method, the compact can be initially heated at from about 50° C. to about 350° C. or about 400° C. to remove the non-polar liquid binder and the spacing agent. The exact temperature can be selected depending on the combination of the non-polar liquid binder and the spacing agent, vacuum conditions, etc. It is desirable to remove the spacing agent at a temperature at which the metal does not react with the spacing agent. In various embodiments, that temperature can range from about 25° C. to about 500° C. In various other embodiments, that temperature can be a temperature less than the melting point of the metal powder. A suitable initial temperature can be at about at least 60° C. or higher, but preferably under the sintering temperature of the selected metal powder. It may be desirable for the initial temperature to be at about or above the boiling point or the sublimation point or decomposition of the binder component having the highest temperature value.
In step 106 the compact is sintered to create a subassembly including a porous metal structure and a metal base. As is known in the art, sintering creates metallic interparticle bonds that provide certain physical and mechanical properties of the porous metal implant. Sintering conditions (temperature, time, and atmosphere) should be such that the metallic interparticle bonds are created while extensive densification is avoided. The sintering can be performed in a controlled atmosphere, such as a vacuum (for example, at 10−5 torr) or under reduced pressure. It may be desirable to conduct the sintering in an inert atmosphere, for example, where the atmosphere is flushed with argon or helium gas prior to initiating the vacuum. Such a vacuum and/or the inert atmosphere will minimize or prevent solid solution hardening of the surface of the porous implant as a result of inward diffusion of oxygen and/or nitrogen into the metal and to prevent formation of oxides on the metal surface. The sintering process can occur using a single-oven or furnace process.
Sintering can be performed at once or in stages. A first sintering of the compact can be conducted to transform the compact (substantially free from metallurgical bonds between the metal powder particles) to the subassembly having metallurgical bonds. The temperature can be increased in a furnace or chamber (by 2° C., 5° C., 10° C., 20° C., 50° C., for example) at time intervals (from 5 seconds to 15 minutes). Once the desired temperature or “hold temperature” is reached, which will vary for the particular metals, the compact is maintained at the hold temperature from about 1 hour to about 10 hours or from about 2 hours to about 6 hours to create the metallurgical bonds between the metal powder particles. The use of temperature intervals can allow for the elimination of separate steps or separate ovens used to remove the spacing agent and the non-polar liquid binder, if used. In various aspects, the step of sintering the compact includes sintering adjacent particles of the porous metal structure to one another and concurrently sintering the porous metal structure to the metal base, providing an integral subassembly.
Once sintered, the subassembly is aligned with a metal substrate portion of an implant, in step 108. As discussed above, the metal substrate may be provided on certain portions of the implant, or in other embodiments, the metal substrate may be on an entirety of the implant. Suitable exemplary metal substrates include Ti6Al4V, CoCrMo alloys (F75 as-cast, F75 HIP-HT, F1537 high C and low C wrought), and commercially pure titanium. In various embodiments, the metal substrate can be specially prepared prior to aligning and attaching the porous body. For example, the porous metal structure, the metal substrate portion, or both, can be machined to a desired shape prior to forming the metallurgical bond between the subassembly and the metal substrate. In certain embodiments, the machining may take place after forming the metallurgical bond. Machining may be performed with an accuracy of between about ten and twenty thousandths of an inch, depending upon the equipment. The metal substrate can be acid etched, subjected to an acid bath, grit blasted, or ultrasonically cleaned for example. Other preparations include adding channels, pits, grooves, indentations, bridges, or holes to the metal substrate. Depending on the overall geometry, these additional features may increase the attachment of the porous metal structure to the underlying metal substrate. Once aligned, a metallurgical bond is formed between the subassembly and the metal substrate portion as referenced by method box 110. In various embodiments, forming the metallurgical bond includes diffusion bonding the metal base of the subassembly to the metal substrate portion, creating an implant having a porous metal component.
After diffusion bonding, the porous metal containing implant can be quenched or rapidly cooled. Quenching can be achieved by direct quenching, fog quenching, hot quenching, interrupted quenching, selective quenching, slack quenching, spray quenching, and/or time quenching. Quenching can be performed in the diffusion bonding oven without moving the implant. For example, with fog quenching, a fog could be distributed through the oven to quench the metal and the fog could be subsequently vacuumed out. In various other embodiments, the cooling can occur for a time period of between about 3 hours and about 20 hours in an inert atmosphere.
The porous metal containing implant can also be attached as part of an orthopaedic insert, such as those disclosed in U.S. patent application Ser. No. 12/038,570 filed Feb. 27, 2008 and published as U.S. Patent Application Publication No. 2008/0147187, Bollinger et al., published Jun. 19, 2008, which is incorporated by reference herein in its entirety. The porous metal containing implant can also be used to form a geostructure, which is a three-dimensional geometric porous engineered structure that is self supporting and is constructed of rigid filaments joined together to form regular or irregular geometric shapes. The structure is described in more detail in U.S. Pat. No. 6,206,924, Timm, issued Mar. 27, 2001 which is incorporated by reference.
In various embodiments, optional agents can be coated onto or in a surface of the porous metal component of the implant. Such optional materials include ceramics, polymers, bone materials, blood products, bioactive materials, and combinations thereof. Such ceramics include resorbable or non-resorbable ceramic materials, such as glasses or ceramics comprising mono-, di-, tri-, α-tri-, β-tri-, and tetra-calcium phosphate, hydroxyapatite, calcium sulfates, calcium oxides, calcium carbonates, magnesium calcium phosphates, phosphate glass, bioglass, and mixtures thereof. Polymers include resorbable or non-resorbable polymers, such as polyhydroxyalkanoates, polylactones and their copolymers. Such polymers include poly(L-lactic acid) (PLLA), poly(D,L-lactide), poly(lactic acid-co-glycolic acid), 50/50 (DL-lactide-co-glycolide), polydioxanone, polycaprolactone and co-polymers and mixtures thereof such as poly(D,L-lactide-co-caprolactone). Bone products include bone powder and demineralized bone. Blood products include blood fractions and other blood derived materials, such as platelet rich plasma. Bioactive agents useful herein include organic molecules, proteins, peptides, peptidomimetics, nucleic acids, nucleoproteins, antisense molecules, polysaccharides, glycoproteins, lipoproteins, carbohydrates and polysaccharides, botanical extracts, and synthetic and biologically engineered analogs thereof, living cells such as stem cells (e.g., adipose derived stem cells) chondrocytes, bone marrow cells, viruses and virus particles, natural extracts, and combinations thereof. Specific examples of bioactive materials include hormones, antibiotics and other antiinfective agents, hematopoietics, thrombopoietics, agents, antiviral agents, antiinflammatory agents, anticoagulants, therapeutic agents for osteoporosis, enzymes, vaccines, immunological agents and adjuvants, cytokines, growth factors, cellular attractants and attachment agents, gene regulators, vitamins, minerals and other nutritionals, nutraceuticals and combinations thereof. For example, the optional material may be a resorbable ceramic, resorbable polymer, antimicrobial, demineralized bone, blood product, stem cell, growth factor or mixture thereof. In various embodiments the optional materials facilitate ingrowth of new tissue into the porous metal implant.
The present technology may be used with implants having a wide range of sizes and geometrical configurations.
The embodiments described herein are exemplary and not intended to be limiting in describing the full scope of compositions and methods of the present technology. Equivalent changes, modifications and variations of embodiments, materials, compositions and methods can be made within the scope of the present technology, with substantially similar results.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3855638 | Pilliar | Dec 1974 | A |
| 4156943 | Collier | Jun 1979 | A |
| 4206271 | Norling et al. | Jun 1980 | A |
| 4309488 | Heide et al. | Jan 1982 | A |
| 4412643 | Sato et al. | Nov 1983 | A |
| 4550448 | Kenna | Nov 1985 | A |
| 4612160 | Donlevy et al. | Sep 1986 | A |
| 4644942 | Sump | Feb 1987 | A |
| 4846393 | Devillard | Jul 1989 | A |
| 4854496 | Bugle | Aug 1989 | A |
| 4957819 | Kawahara et al. | Sep 1990 | A |
| 5027998 | Bugle | Jul 1991 | A |
| 5047182 | Sundback et al. | Sep 1991 | A |
| 5080672 | Bellis | Jan 1992 | A |
| 5080674 | Jacobs et al. | Jan 1992 | A |
| 5096518 | Fujikawa et al. | Mar 1992 | A |
| 5104410 | Chowdhary | Apr 1992 | A |
| 5126103 | Ishizaki et al. | Jun 1992 | A |
| 5198308 | Shetty et al. | Mar 1993 | A |
| 5201766 | Georgette | Apr 1993 | A |
| 5282861 | Kaplan | Feb 1994 | A |
| 5323954 | Shetty et al. | Jun 1994 | A |
| 5348788 | White | Sep 1994 | A |
| 5443510 | Shetty et al. | Aug 1995 | A |
| 5504300 | Devanathan et al. | Apr 1996 | A |
| 5507824 | Lennox | Apr 1996 | A |
| 5535810 | Compton et al. | Jul 1996 | A |
| 5688453 | England et al. | Nov 1997 | A |
| 5702458 | Burstein et al. | Dec 1997 | A |
| 5734959 | Krebs et al. | Mar 1998 | A |
| 5926685 | Krebs et al. | Jul 1999 | A |
| 6022509 | Matthews et al. | Feb 2000 | A |
| 6066176 | Oshida | May 2000 | A |
| 6132674 | Compton et al. | Oct 2000 | A |
| 6206924 | Timm | Mar 2001 | B1 |
| 6458161 | Gibbs et al. | Oct 2002 | B1 |
| 6495448 | Lee | Dec 2002 | B1 |
| 6527809 | Doursounian et al. | Mar 2003 | B1 |
| 6544472 | Compton et al. | Apr 2003 | B1 |
| 6605648 | Johnson et al. | Aug 2003 | B1 |
| 6660224 | Lefebvre et al. | Dec 2003 | B2 |
| 6913623 | Zhu | Jul 2005 | B1 |
| 6945448 | Medlin et al. | Sep 2005 | B2 |
| 7147819 | Bram et al. | Dec 2006 | B2 |
| 7291177 | Gibbs | Nov 2007 | B2 |
| 7351371 | Nelles et al. | Apr 2008 | B2 |
| 7597715 | Brown et al. | Oct 2009 | B2 |
| 7635447 | Hamman et al. | Dec 2009 | B2 |
| 7713306 | Gibbs | May 2010 | B2 |
| 7883661 | Hamman et al. | Feb 2011 | B2 |
| 20020062154 | Ayers | May 2002 | A1 |
| 20030083741 | Woo et al. | May 2003 | A1 |
| 20030153981 | Wang et al. | Aug 2003 | A1 |
| 20030171820 | Wilshaw et al. | Sep 2003 | A1 |
| 20030200837 | Matsuura et al. | Oct 2003 | A1 |
| 20030220696 | Levine et al. | Nov 2003 | A1 |
| 20030232124 | Medlin et al. | Dec 2003 | A1 |
| 20040064192 | Bubb | Apr 2004 | A1 |
| 20040072010 | Date et al. | Apr 2004 | A1 |
| 20040109853 | McDaniel | Jun 2004 | A1 |
| 20040137218 | Liu et al. | Jul 2004 | A1 |
| 20050031704 | Ahn | Feb 2005 | A1 |
| 20050048193 | Li et al. | Mar 2005 | A1 |
| 20050100470 | Lefebvre et al. | May 2005 | A1 |
| 20050145364 | Nakajima | Jul 2005 | A1 |
| 20050184134 | Charlebois et al. | Aug 2005 | A1 |
| 20050234559 | Fernandez et al. | Oct 2005 | A1 |
| 20050242162 | Medlin et al. | Nov 2005 | A1 |
| 20060002810 | Grohowski, Jr. | Jan 2006 | A1 |
| 20060018942 | Rowe et al. | Jan 2006 | A1 |
| 20060241776 | Brown et al. | Oct 2006 | A1 |
| 20060241781 | Brown et al. | Oct 2006 | A1 |
| 20070129809 | Meridew et al. | Jun 2007 | A1 |
| 20070150068 | Dong et al. | Jun 2007 | A1 |
| 20070173948 | Meridew et al. | Jul 2007 | A1 |
| 20070196230 | Hamman et al. | Aug 2007 | A1 |
| 20070243312 | Bulko | Oct 2007 | A1 |
| 20070250175 | Meridew et al. | Oct 2007 | A1 |
| 20070264152 | Zhao | Nov 2007 | A1 |
| 20080027556 | Metzger | Jan 2008 | A1 |
| 20080147187 | Bollinger et al. | Jun 2008 | A1 |
| 20080195222 | Rauguth et al. | Aug 2008 | A1 |
| 20080199343 | Rust et al. | Aug 2008 | A1 |
| 20090084491 | Uthgenannt et al. | Apr 2009 | A1 |
| 20090098310 | Hippensteel et al. | Apr 2009 | A1 |
| 20100004754 | Brown et al. | Jan 2010 | A1 |
| 20100074789 | Heuer et al. | Mar 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 3130732 | May 1983 | DE |
| 19726961 | Nov 1998 | DE |
| 1421918 | May 2004 | EP |
| 3837502 | Aug 2006 | JP |
| WO 2004080340 | Sep 2004 | WO |
| WO 2006007861 | Jan 2006 | WO |
| Entry |
|---|
| Bram et al. “High-Porosity Titanium, Stainless Steel, and Superalloy Parts” Advanced Engineering Materials, vol. 2, No. 4 (2000) pp. 196-199. |
| Laptev, A. et al. “Study of Production Route for Titanium Parts Combining Very High Porosity and Complex Shape” Powder Metallurgy, vol. 47, No. 1 (2004) pp. 85-92. |
| Oliveira et al. “Porous Structure Characterization in Titanium Coating for Surgical Implants” Materials Research, vol. 5, No. 3 (2002) pp. 269-273. |
| Wen, C.E. et al. “Novel Titanium Foam for Bone Tissue Engineering” J. Mater. Res., vol. 17, No. 10 (2002) pp. 2633-2639. |
| Wen, C.E. et al. “Processing and Mechanical Properties of Autogenous Titanium Implant Materials” Journal of Materials Science: Materials in Medicine 13 (2002) pp. 397-401. |
| Wen, C.E. et al. “Processing of Biocompatible Porous Ti and Mg” Scripta Materialia 45 (2001) pp. 1147-1153. |
| Wheeler, K.R. et al. “Porous Metals as a Hard Tissue Substitute. Part II: Porous Metal Properties” Biomat., Med. Dev., Art. Org., 1(2), (1973) pp. 337-348. |
| Li, J. et al. “A Novel Porous Ti6AI4V: Characterization and Cell Attachment” Journal of Biomedical Materials Research, vol. 73a, No. 2, pp. 223-233 (May 2005). |
| Mahoney, M. and Bampton, C. “Fundamentals of Diffusion Bonding” ASM Handbook, vol. 6 (1994), pp. 156-159. |
| Number | Date | Country | |
|---|---|---|---|
| 20110085929 A1 | Apr 2011 | US |
